Kinase Inhibitor Drugs / Wiley series in drug discovery and development (ePub)
(Sprache: Englisch)
A comprehensive resource on case studies of marketed kinase
drugs and promising drug trials
Since the discovery of protein kinase activity in 1954, the
field of protein kinase drug discovery has advanced dramatically.
With the ongoing clinical success...
drugs and promising drug trials
Since the discovery of protein kinase activity in 1954, the
field of protein kinase drug discovery has advanced dramatically.
With the ongoing clinical success...
sofort als Download lieferbar
eBook (ePub)
141.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Kinase Inhibitor Drugs / Wiley series in drug discovery and development (ePub)“
A comprehensive resource on case studies of marketed kinase
drugs and promising drug trials
Since the discovery of protein kinase activity in 1954, the
field of protein kinase drug discovery has advanced dramatically.
With the ongoing clinical success of the Bcr-Abl kinase inhibitor
Gleevec in the treatment of chronic myelogenous leukemia and seven
additional marketed kinase inhibitor drugs, researchers have
compelling evidence that kinase inhibitors can be highly
efficacious in the treatment of diseases caused by aberrant
activity of protein kinase. Currently more than 100 protein kinase
inhibitors are in clinical development.
In one comprehensive volume, the editors, Dr. Rongshi Li and Dr.
Jeffrey Stafford, present timely and important case studies of
marketed kinase drugs and several of the most advanced kinase
inhibitors in clinical trials. Kinase Inhibitor Drugs
includes:
* Case studies from leading investigators and experts in the field
that provide firsthand accounts of kinase inhibitor discovery
* Current thinking on kinase structure, biochemistry, and signal
transduction pathways
* Information on state-of-the-art technologies and tools such as
structure-based and fragment-based drug discovery
* A lineup of clinical-phase growth factor receptor inhibitors
* Inhibitors of cell cycle kinases
* The discovery of allosteric inhibitors of MEK kinase
* Information on pharmacogenomics and its application to kinase
inhibitor clinical development
drugs and promising drug trials
Since the discovery of protein kinase activity in 1954, the
field of protein kinase drug discovery has advanced dramatically.
With the ongoing clinical success of the Bcr-Abl kinase inhibitor
Gleevec in the treatment of chronic myelogenous leukemia and seven
additional marketed kinase inhibitor drugs, researchers have
compelling evidence that kinase inhibitors can be highly
efficacious in the treatment of diseases caused by aberrant
activity of protein kinase. Currently more than 100 protein kinase
inhibitors are in clinical development.
In one comprehensive volume, the editors, Dr. Rongshi Li and Dr.
Jeffrey Stafford, present timely and important case studies of
marketed kinase drugs and several of the most advanced kinase
inhibitors in clinical trials. Kinase Inhibitor Drugs
includes:
* Case studies from leading investigators and experts in the field
that provide firsthand accounts of kinase inhibitor discovery
* Current thinking on kinase structure, biochemistry, and signal
transduction pathways
* Information on state-of-the-art technologies and tools such as
structure-based and fragment-based drug discovery
* A lineup of clinical-phase growth factor receptor inhibitors
* Inhibitors of cell cycle kinases
* The discovery of allosteric inhibitors of MEK kinase
* Information on pharmacogenomics and its application to kinase
inhibitor clinical development
Inhaltsverzeichnis zu „Kinase Inhibitor Drugs / Wiley series in drug discovery and development (ePub)“
PREFACE. CONTRIBUTORS. PART I GROWTH FACTOR INHIBITORS: VEGFR2, ERBB2, AND OTHER KINASE. 1 Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis (Connie L. Sun, James G. Christensen, and Gerald McMahon). 2 Tykerb Discovery: A Dual EGFR and ERBB2 Tyrosine Kinase Inhibitor (Karen Lackey and G. Stuart Cockerill). 3 Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor (Philip A. Harris and Jeffrey A. Stafford). 4 Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor (Michael Michaelides and Daniel H. Albert). 5 Discovery of Motesanib (Andrew S. Tasker and Vinod F. Patel). 6 Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor (Rajeev S. Bhide and Joseph Fargnoli). 7 S tructure-Based Design and Characterization of Axitinib (Robert S. Kania). PART II GROWTH FACTOR INHIBITORS: MEK INHIBITORS. 8 Road to PD0325901 and Beyond: The MEK Inhibitor Quest (Judith S. Sebolt-Leopold and Alexander J. Bridges). 9 Discovery of Allosteric MEK Inhibitors (Eli Wallace and James F. Blake). PART III CELL CYCLE KINASE INHIBITORS: AURORA KINASE AND PLK INHIBITORS. 10 Discovery of MK-0457 (VX-680) (Julian M. C. Golec). 11 Discovery of PHA-739358 (Daniele Fancelli and Jürgen Moll). 12 Discovery of AZD1152: A Selective Inhibitor of Aurora-B Kinase with Potent Antitumor Activity (Kevin M. Foote and Andrew A. Mortlock). 13 Case Study of Aurora-A Inhibitor MLN8054 (Christopher F. Claiborne and Mark G. Manfredi). 14 Discovery of GSK461364: A Polo-like Kinase 1 Inhibitor for the Treatment of Cancer (Kevin W. Kuntz and Kyle A. Emmitte). PART IV RELATED SPECIAL TOPICS. 15 Pharmacogenomics of Dasatinib (Sprycel) (Fei Huang and Edwin A. Clark). 16 Practical Use of Computational Chemistry in Kinase Drug Discovery (James M. Veal). 17 Approaches to Kinase Homology Modeling: Successes and Considerations for the
... mehr
Structural Kinome (Victoria A. Feher and J. David Lawson). 18 Fragment-Based Drug Discovery of Kinase Inhibitors (Daniel A. Erlanson). 19 Protein Kinase Structural Biology: Methods and Strategies for Targeted Drug Discovery (Clifford D. Mol, Kengo Okada, and David J. Hosfield). INDEX.
... weniger
Autoren-Porträt von Rongshi Li, Jeffrey A. Stafford
Rongshi Li, PhD, is an Associate Professor in the DrugDiscovery Department at H. Lee Moffitt Cancer Center and Research
Institute in Tampa, Florida.
Jeffrey A. Stafford, PhD, has led drug discovery research
at GlaxoSmithKline, Syrrx, and Takeda. He is a co-inventor of the
tyrosine kinase inhibitor, pazopanib (Armala).
Bibliographische Angaben
- Autoren: Rongshi Li , Jeffrey A. Stafford
- 2011, 1. Auflage, 528 Seiten, Englisch
- Verlag: John Wiley & Sons
- ISBN-10: 1118210905
- ISBN-13: 9781118210901
- Erscheinungsdatum: 20.09.2011
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: ePub
- Größe: 22 MB
- Mit Kopierschutz
Sprache:
Englisch
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Kommentar zu "Kinase Inhibitor Drugs / Wiley series in drug discovery and development"
0 Gebrauchte Artikel zu „Kinase Inhibitor Drugs / Wiley series in drug discovery and development“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Kinase Inhibitor Drugs / Wiley series in drug discovery and development".
Kommentar verfassen